Pre-Treatment Whole Blood Gene Expression Is Associated with 14-Week Response Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging in Infliximab-Treated Rheumatoid Arthritis Patients

• Kenzie D. MacIsaac ,

  * E-mail: kenzie_macisaac@merck.com

  Affiliation Merck & Co. Inc., Department of Genetics and Pharmacogenomics, Boston, Massachusetts, United States of America

  ⨯
• Richard Baumgartner,

  Affiliation Merck & Co. Inc., Department of Biometrics Research, Whitehouse Station, New Jersey, United States of America

  ⨯
• Jia Kang,

  Affiliation Merck & Co. Inc., Department of Biometrics Research, Whitehouse Station, New Jersey, United States of America

  ⨯
• Andrey Loboda,

  Affiliation Merck & Co. Inc., Department of Genetics and Pharmacogenomics, Boston, Massachusetts, United States of America

  ⨯
• Charles Peterfy,

  Affiliation Spire Sciences Inc., Boca Raton, Florida, United States of America

  ⨯
• Julie DiCarlo,

  Affiliation Spire Sciences Inc., Boca Raton, Florida, United States of America

  ⨯
• Jonathan Riek,

  Affiliation Virtual Scopics, Rochester, New York, United States of America

  ⨯
• Chan Beals

  Affiliation Merck & Co. Inc., Clinical Research, Whitehouse Station, New Jersey, United States of America

  ⨯